| Heterogeneous blood–tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer PR Lockman, RK Mittapalli, KS Taskar, V Rudraraju, B Gril, KA Bohn, ... Clinical Cancer Research 16 (23), 5664-5678, 2010 | 677 | 2010 |
| Orodispersible tablets: An overview S Bandari, RK Mittapalli, R Gannu Asian Journal of Pharmaceutics (AJP) 2 (1), 2008 | 569 | 2008 |
| Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer FC Thomas, K Taskar, V Rudraraju, S Goda, HR Thorsheim, JA Gaasch, ... Pharmaceutical research 26 (11), 2486-2494, 2009 | 262 | 2009 |
| Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma RK Oberoi, KE Parrish, TT Sio, RK Mittapalli, WF Elmquist, JN Sarkaria Neuro-oncology 18 (1), 27-36, 2015 | 259 | 2015 |
| Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer KS Taskar, V Rudraraju, RK Mittapalli, R Samala, HR Thorsheim, ... Pharmaceutical Research, 1-12, 2012 | 228 | 2012 |
| Mechanisms limiting distribution of the threonine-protein kinase B-RaFV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases RK Mittapalli, S Vaidhyanathan, AZ Dudek, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 344 (3), 655-664, 2013 | 185 | 2013 |
| Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks D Palmieri, PR Lockman, FC Thomas, E Hua, J Herring, E Hargrave, ... Clinical Cancer Research 15 (19), 6148-6157, 2009 | 176 | 2009 |
| Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) RK Mittapalli, S Vaidhyanathan, R Sane, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 342 (1), 33-40, 2012 | 175 | 2012 |
| Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-gp, BCRP, and P-gp/BCRP Knockout Mice S Agarwal, Y Uchida, RK Mittapalli, R Sane, T Terasaki, WF Elmquist Drug Metabolism and Disposition, 2012 | 156* | 2012 |
| Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents S Agarwal, RK Mittapalli, DM Zellmer, JL Gallardo, R Donelson, C Seiler, ... Molecular cancer therapeutics 11 (10), 2183-2192, 2012 | 113 | 2012 |
| Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases S Vaidhyanathan, RK Mittapalli, JN Sarkaria, WF Elmquist Drug Metabolism and Disposition 42 (8), 1292-1300, 2014 | 108 | 2014 |
| Paclitaxel–hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model RK Mittapalli, X Liu, CE Adkins, MI Nounou, KA Bohn, TB Terrell, ... Molecular cancer therapeutics 12 (11), 2389-2399, 2013 | 108 | 2013 |
| Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model KE Parrish, J Pokorny, RK Mittapalli, K Bakken, JN Sarkaria, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 355 (2), 264-271, 2015 | 102 | 2015 |
| Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system KE Parrish, L Cen, J Murray, D Calligaris, S Kizilbash, RK Mittapalli, ... Molecular cancer therapeutics 14 (12), 2735-2743, 2015 | 91 | 2015 |
| Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain RK Oberoi, RK Mittapalli, WF Elmquist Journal of Pharmacology and Experimental Therapeutics 347 (3), 755-764, 2013 | 88 | 2013 |
| Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules RK Mittapalli, VK Manda, CE Adkins, WJ Geldenhuys, PR Lockman Therapeutic Delivery 1 (6), 775-784, 2010 | 74 | 2010 |
| Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study BG Czito, DA Deming, GS Jameson, MF Mulcahy, H Vaghefi, MW Dudley, ... The lancet Gastroenterology & hepatology 2 (6), 418-426, 2017 | 66 | 2017 |
| ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B–Driven brainstem glioma model RK Mittapalli, AH Chung, KE Parrish, D Crabtree, KG Halvorson, G Hu, ... Molecular cancer therapeutics 15 (5), 819-829, 2016 | 64 | 2016 |
| P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model CE Adkins, RK Mittapalli, VK Manda, MI Nounou, AS Mohammad, ... Frontiers in pharmacology 4, 136, 2013 | 63 | 2013 |
| Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors RK Mittapalli, CE Adkins, KA Bohn, AS Mohammad, JA Lockman, ... Cancer research 77 (2), 238-246, 2017 | 60 | 2017 |
